FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical composition for the treatment of cancer comprising a compound of the formula indicated below, where the cancer is selected from the group consisting of multiple myeloma, lymphoma, breast cancer, prostate cancer, lung cancer, kidney cancer, thyroid cancer, ovarian cancer, pancreatic cancer, colorectal cancer, neuroblastoma, astrocytoma, medulloblastoma, glioma, melanoma, carcinomas of the thyroid gland, adenocarcinoma of the lungs, metastasizing bone disease, neuroendocrine tumor of large cells.
.
EFFECT: treatment of cancer.
27 cl, 105 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TROPOMYOSIN-RELATED KINASE INHIBITORS | 2009 |
|
RU2523544C2 |
| SUBSTITUTED COMPOUNDS OF PYRAZOLE[1,5-a]PYRIMIDINE AS TRK KINASE INHIBITORS | 2010 |
|
RU2584157C2 |
| PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | 2012 |
|
RU2606131C2 |
| CONDENSED RING HETEROARYL COMPOUNDS AND USE THEREOF AS TRK INHIBITORS | 2015 |
|
RU2708674C2 |
| N-PYRROLIDINYL-UREA, N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | 2013 |
|
RU2677667C2 |
| HETEROCYCLIC DIHYDROPYRIMIDINE COMPOUNDS | 2000 |
|
RU2296766C2 |
| CONDENSED AZA-HETEROCYCLIC AMIDE COMPOUND AND ITS USE | 2021 |
|
RU2811975C1 |
| SERINE/THREONINE KINASE INHIBITORS | 2013 |
|
RU2650501C2 |
| POINT MUTATIONS IN TRK INHIBITOR-RESISTANT MALIGNANT TUMORS AND RELATED METHODS | 2016 |
|
RU2744852C2 |
| COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
